ORGS Nasdaq

Orgenesis Inc.

ORGS | $0.5032 -1.74% 30K

(0.0% 1d) (-43.3% 1m) (-52.3% 1y) (0.0% 2d) (0.0% 3d) (2.1% 7d) (-37.05% volume)
Earnings Calendar: 2024-04-15
Market Cap: $ 17,279,275
http://www.orgenesis.com
Sec Filling | Patents | 309 employees

(United States) Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

gene therapies immunotherapy neurodegenerative t-cell metabolic ceiling

add to watch list Paper trade email alert is off

Press-releases

Orgenesis Provides Year End Business Update
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology

| 2.06% | O: -1.94% H: 11.47% C: 2.04%
business year update

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
Published: 2024-04-10 (Crawled : 16:00) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology

| 5.15% | O: 7.22% H: 69.23% C: 0.73%
partnership cell global therapy

Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
Published: 2024-03-13 (Crawled : 12:30) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology

| -40.7% | O: 3.36% H: 1.24% C: 0.39%
grant

Orgenesis Inc. Announces $2.3 Million Private Placement
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology

| -25.1% | O: 1.34% H: 12.32% C: 11.16%
million

Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
Published: 2024-02-29 (Crawled : 13:30) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology

| -18.14% | O: 1.12% H: 5.7% C: 1.62%
grant

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
Published: 2024-01-31 (Crawled : 14:00) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology

| 59.52% | O: 6.35% H: 0.0% C: -7.65%
control

Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
Published: 2023-11-14 (Crawled : 13:30) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology

| -8.67% | O: -10.46% H: 22.02% C: 10.04%
america company technology 500

Orgenesis Provides Business Update for the Third Quarter of 2023
Published: 2023-11-13 (Crawled : 21:00) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology

| -8.67% | O: -10.46% H: 22.02% C: 10.04%
business update

Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
Published: 2023-11-08 (Crawled : 14:00) - globenewswire.com
ORGS | $0.5032 -1.74% 30K

Health Technology